|
|
||||||||
1From the Departments of Biomolecular Recognition and Ophthalmology and 3Ocular Pathophysiology, Yamaguchi University School of Medicine, Ube City, Japan; and the 2Department of Ophthalmology, Jilin University School of Medicine, Changchun, China.
| Abstract |
|---|
|
|
|---|
METHODS. The release of IL-8 and MCP-1 from and the surface expression of ICAM-1 on cultured corneal fibroblasts were measured with enzyme-linked immunosorbent assays. The cellular abundance of the mRNAs for these proteins was determined by reverse transcription and real-time polymerase chain reaction analysis. The activities of the transcription factors NF-
B and AP-1 were assessed by cell transfection with secretory alkaline phosphatase reporter genes.
RESULTS. Both triptolide and dexamethasone inhibited in a dose-dependent manner the expression of IL-8 and MCP-1 in corneal fibroblasts induced by the proinflammatory cytokines IL-1ß or tumor necrosis factor (TNF)-
. These inhibitory effects were apparent at both the mRNA and protein levels. Both compounds also had a lesser inhibitory effect on cytokine-induced ICAM-1 expression. The activation of NF-
B by IL-1ß was markedly inhibited by both triptolide and dexamethasone, whereas the activity of AP-1 was not affected by either agent.
CONCLUSIONS. Like dexamethasone, triptolide inhibited IL-8 and MCP-1 expression in cultured human corneal fibroblasts exposed to proinflammatory cytokines, an action most likely mediated by inhibition of NF-
B activation. Similar effects of triptolide in vivo may be expected to limit the infiltration of neutrophils and monocytes into the cornea.
Steroid administration is effective in the treatment of some cases of corneal inflammatory disease. Steroids affect the functions of both immune cells and resident corneal cells. However, their use is associated with adverse ocular effects, such as recurrence of infection, increased intraocular pressure, and the development of posterior subcapsular cataract,5 as well as with systemic complications such as osteoporosis.6 Extracts of the Chinese herb Tripterygium wilfordii hook f, the major constituent of which is the diterpene triepoxide triptolide, have been used in traditional Chinese medicine for the treatment of rheumatoid arthritis.7 Triptolide exhibits anti-inflammatory activity with immune cells such as T cells, B cells, and monocytes.8 9 It also acts on tissue-resident cells such as epithelial cells10 and fibroblasts,11 inhibiting the expression of IL-8 in bronchial epithelial cells.10 We recently showed that triptolide inhibits collagen degradation by corneal fibroblasts.12 In the present study, we examined the possible effects of triptolide, in comparison with those of dexamethasone, both on the expression of IL-8, MCP-1, and ICAM-1 and on the activities of the transcription factors nuclear factor (NF)-
B and activator protein (AP)-1 in corneal fibroblasts stimulated with the proinflammatory cytokines IL-1ß or tumor necrosis factor (TNF)-
.
| Methods |
|---|
|
|
|---|
and IL-1ß and enzyme-linked immunosorbent assay (ELISA) kits for IL-8 and MCP-1 from R&D Systems (Minneapolis, MN); a mouse monoclonal antibody to ICAM-1 from BD-PharMingen (San Diego, CA); and horseradish peroxidaseconjugated goat antibodies to mouse IgG from Chemicon (Temecula, CA); PCR kits (RNeasy Mini and QuantiTect SYBR Green) from Qiagen (Hilden, Germany); a reverse transcription system from Promega (Madison, WI); lipid transfection reagent (TransFectin) from Bio-Rad (Hercules, CA); pNF-
B-secretory alkaline phosphatase (SEAP), pAP-1-SEAP vectors, and a SEAP fluorescence detection kit (BD Great EscAPe) from BD Biosciences (San Jose, CA); and the pM1-CAT vector and a chloramphenicol acetyltransferase (CAT) ELISA kit from Roche Molecular Biochemicals (Mannheim, Germany). All media and reagents used for cell culture were endotoxin minimized.
Isolation and Culture of Human Corneal Fibroblasts
Human corneas were obtained for corneal transplantation surgery from the NorthWest Lions Eye Bank (Seattle, WA). The human tissue was used in strict accordance with the tenets of the Declaration of Helsinki. Corneal fibroblasts were prepared and cultured as described previously.13 In brief, the endothelial layer of the rim of the cornea remaining after corneal transplantation surgery was removed mechanically, and the tissue was then incubated with dispase (2 mg/mL in MEM) for 1 hour. After mechanical removal of the epithelial sheet, the tissue was treated with collagenase (2 mg/mL in MEM) until a single-cell suspension of corneal fibroblasts was obtained. The cells were cultured in MEM supplemented with 10% FBS and were used for experiments after four to seven passages under subconfluent (actively proliferating) conditions. The purity of the corneal fibroblast cultures was judged on the basis of both cell morphology and reactivities with antibodies to vimentin and cytokeratin, as previously described.13 All the cells were positive for vimentin and negative for cytokeratin, suggesting that the cultures were not contaminated by epithelial cells. No changes in cell morphology or immunoreactivity were apparent after culture for up to four to seven passages. Immunofluorescence analysis with antibodies to
-smooth muscle actin also revealed that the passaged cells did not express this protein, indicating that they were not transformed myofibroblasts.
Assay of IL-8 and MCP-1 Release
Corneal fibroblasts were cultured in 24-well plates until they achieved confluence, after which the culture medium was replaced with serum-free MEM for 1 day. The cells were then incubated first for 1 hour with various concentrations of triptolide (0.330 nM) or dexamethasone (0.01100 nM) and then for an additional 24 hours in the same medium supplemented with IL-1ß (1 ng/mL) or TNF-
(1 ng/mL). The culture medium was then collected and centrifuged at 120g for 5 minutes, and the resultant supernatant was frozen at 80°C for subsequent measurement of IL-8 and MCP-1 concentrations by ELISA. The cells were detached from the culture plate by exposure to trypsin-EDTA, and their number was determined with a hemocytometer. Given that the morphology and number of cells were not affected by incubation with IL-1ß, TNF-
, triptolide, or dexamethasone for 24 hours, the concentrations of IL-8 and MCP-1 in the culture supernatants were normalized by expression as nanograms of chemokine per 1 x 106 cells.
Whole-Cell ELISA for ICAM-1
A whole-cell ELISA for ICAM-1 was performed as described previously.14 In brief, corneal fibroblasts (1 x 103 cells per well) were grown for 3 days in 96-well plates in MEM supplemented with 10% FBS, after which the culture medium was changed to serum-free MEM for 1 day. The cells were subsequently incubated, first for 1 hour with various concentrations of triptolide (0.330 nM) or dexamethasone (0.01100 nM) and then for an additional 24 hours in the same medium supplemented with IL-1ß (1 ng/mL) or TNF-
(1 ng/mL). The medium was then aspirated, and the cells were washed twice with phosphate-buffered saline (PBS), fixed for 15 minutes at room temperature with PBS containing 1% paraformaldehyde, washed with PBS, and incubated for 1 hour at 37°C with a monoclonal antibody to ICAM-1 (1:10,000 dilution) in PBS containing 1% bovine serum albumin (BSA). After they were washed three times with PBS containing 0.1% BSA, the cells were incubated for 1 hour with horseradish peroxidaseconjugated goat antibodies to mouse IgG, washed another three times with PBS containing 0.1% BSA, and incubated for 20 minutes in the dark with 100 µL tetramethylbenzidine solution. The reaction was terminated by the addition of 50 µL of 1 M H2SO4, and the absorbance of each well was measured at 450 nm with a microplate reader. The expression of ICAM-1 was calculated as a percentage of the control value.
Quantitative RT-PCR Analysis
The abundance of IL-8, MCP-1, and ICAM-1 mRNAs was determined by reverse transcription (RT) and real-time polymerase chain reaction (PCR) analysis, as described previously.15 The medium of confluent corneal fibroblasts cultured in 60-mm dishes was changed to serum-free MEM, and the cells were cultured for an additional 24 hours before incubation, first for 1 hour with 30 nM triptolide or 100 nM dexamethasone and then for an additional 4 hours in the same medium supplemented with IL-1ß (1 ng/mL) or TNF-
(1 ng/mL). Total RNA was then extracted from the fibroblasts and subjected to RT, and the resultant cDNA was subjected to real-time PCR with a thermocycler (LightCycler; Roche Molecular Biochemicals). Transcripts of the constitutively expressed gene for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served to normalize the amounts of IL-8, MCP-1, and ICAM-1 mRNAs in each sample. Real-time PCR data were analyzed with the thermocycler software (LightCycler ver. 3.1; Roche Molecular Biochemicals). To verify the specificity of amplification, we also subjected PCR products to electrophoresis on a 3% agarose gel, which was then stained with ethidium bromide (1 µg/mL) and examined (Nighthawk system; pdi, Huntington Station, NY). The sequences of the PCR primers for ICAM-1 were 5'-TAAGCCAAGAGGAAGGAGCA-3' (forward) and 5'-CATATCATCAAGGGTTGGGG-3' (reverse). Primer sequences for GAPDH, IL-8, and MCP-1 have been described.16
Transient Transfection
Human corneal fibroblasts (3 x 104 per well) were maintained in 24-well plates for 24 hours in MEM supplemented with 10% FBS and were then transfected in modified Eagles MEM (Opti-MEM; Invitrogen-Gibco) with pM1-CAT and either pNF-
B-SEAP or pAP-1-SEAP at a ratio of 1:4 for 4 hours with the use of transfection reagent (TransFectin; Bio-Rad). The cells were cultured for 20 hours in the preservative and then incubated in the absence or presence of IL-1ß (10 ng/mL), with or without triptolide (30 nM) or dexamethasone (100 nM), for an additional 48 hours. The culture supernatants were assayed for SEAP activity, and cell lysates were assayed for CAT by ELISA, to normalize transfection efficiency.
Statistical Analysis
Data are presented as the mean ± SEM and were analyzed by the Dunnett multiple comparison test or Students unpaired t-test. P < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
on IL-8, MCP-1, and ICAM-1 expression by human corneal fibroblasts. Consistent with previous observations,14 17 incubation of the cells for 24 hours in the presence of IL-1ß (1 ng/mL) or TNF-
(1 ng/mL) resulted in 54- and 44-fold increases in the amount of IL-8 in the culture medium (Fig. 1A) , 25- and 23-fold increases in the amount of MCP-1 in the culture medium (Fig. 1B) , and 2.1- and 2.3-fold increases in the surface abundance of ICAM-1 (Fig. 1C) , respectively.
|
We next investigated the effects of triptolide and dexamethasone on IL-8, MCP-1, and ICAM-1 expression in corneal fibroblasts treated with IL-1ß or TNF-
. The cells were incubated with various concentrations of triptolide or dexamethasone for 1 hour before incubation for 24 hours in the additional absence or presence of IL-1ß (1 ng/mL) or TNF-
(1 ng/mL). Triptolide induced a small inhibitory effect on IL-8 release at a concentration of 10 nM, but otherwise did not significantly modify the basal expression of this chemokine (Fig. 2A) . In contrast, triptolide significantly inhibited IL-1ß- or TNF-
-induced IL-8 release in a dose-dependent manner. At a concentration of 30 nM, triptolide inhibited this effect of IL-1ß by 52% and that of TNF-
by 43%. Dexamethasone exhibited effects similar to those of triptolide on basal as well as Il-1ß- or TNF-
-induced IL-8 release (Fig. 2B) . At 100 nM, it inhibited this effect of IL-1ß by 60% and that of TNF-
by 44%.
|
-induced MCP-1 release in a dose-dependent manner. At a concentration of 30 nM, triptolide inhibited the effect of IL-1ß by 75% and that of TNF-
by 66%. Dexamethasone induced a small inhibitory effect on basal MCP-1 release at a concentration of 10 nM. It also inhibited in a dose-dependent manner the MCP-1 expression induced by IL-1ß or TNF-
(Fig. 3B) . At 100 nM, dexamethasone inhibited the effect of IL-1ß by 64% and that of TNF-
by 57%.
|
by 37% and 30%, respectively, but it had no significant effect on ICAM-1 expression at other concentrations examined (Fig. 4A) . Dexamethasone (100 nM) inhibited the effect of IL-1ß on ICAM-1 expression by 29% but otherwise had no significant effect on ICAM-1 expression (Fig. 4B) .
|
(1 ng/mL) for 4 hours resulted in 930- and 610-fold increases, respectively, in the amount of IL-8 mRNA, and that triptolide (30 nM) inhibited these effects by 72% and 85%, respectively, whereas dexamethasone (100 nM) inhibited them by 50% and 60%, respectively (Fig. 5A) . IL-1ß or TNF-
induced 146- and 56-fold increases, respectively, in the amount of MCP-1 mRNA in corneal fibroblasts, and triptolide (30 nM) inhibited these effects by 88% and 76%, respectively, whereas dexamethasone (100 nM) inhibited them by 81% and 65%, respectively (Fig. 5B) . IL-1ß or TNF-
induced 91- and 130-fold increases, respectively, in the amount of ICAM-1 mRNA in corneal fibroblasts, and triptolide (30 nM) inhibited each of these effects by 32%, whereas dexamethasone (100 nM) inhibited the effect of IL-1ß by 49% and that of TNF-
by 51% (Fig. 5C) .
|
B and AP-1 Activity in Corneal Fibroblasts
B or AP-1 are inhibited by triptolide or dexamethasone, we transfected corneal fibroblasts with pNF-
B-SEAP or pAP-1-SEAP plasmids together with pM1-CAT. After incubation of the transfected cells in the absence or presence of IL-1ß (10 ng/mL), 30 nM triptolide, or 100 nM dexamethasone for 48 hours, the culture supernatants were assayed for SEAP activity, and cell lysates were assayed for CAT by ELISA. Determination of the SEAP/CAT ratio revealed that IL-1ß induced a twofold increase in the transactivation activity of NF-
B and that triptolide or dexamethasone inhibited this effect by 39% and 17%, respectively (Fig. 6) . In contrast, neither IL-1ß, triptolide, nor dexamethasone affected the transactivation activity of AP-1 (Fig. 7) .
|
|
| Discussion |
|---|
|
|
|---|
or IL-1ß. Both triptolide and dexamethasone inhibited the cytokine-induced expression of ICAM-1 on the surface of these cells only at the highest concentration examined, however. Inhibition of NF-
B activity, but not of AP-1 activity, accompanied and may contribute to the effects of triptolide and dexamethasone on chemokine production. Our results thus suggest that triptolide may downregulate IL-8 and MCP-1 expression in corneal fibroblasts in vivo and thereby limit the local accumulation of neutrophils and monocytes in the corneal stroma.
The regulation of corneal fibroblasts by cytokines is likely to be an important determinant of neutrophil and monocyte recruitment to ocular lesions. Various cytokines released into tear fluid affect corneal fibroblast function either individually or cooperatively. The concentration of IL-1 in tear fluid is increased in individuals with corneal ulcer.18 Inhibition of IL-1 action by an IL-1 receptor antagonist reduces the severity of mouse bacterial keratitis,19 indicating the importance of this cytokine in the pathogenesis of stromal melting. The level of TNF-
in tear fluid is also increased in individuals with vernal keratoconjunctivitis and correlates with the severity of disease.20 We have now shown that, in human corneal fibroblasts, triptolide inhibited, in a dose-dependent manner, the expression of IL-8 and MCP-1, at both the protein and mRNA levels, induced by proinflammatory cytokines.
Leukocytes play important roles in the pathogenesis of corneal inflammatory diseases. We recently showed that keratocytes release chemokines that may facilitate the chemotaxis of leukocytes to the corneal stroma.15 Various mediators have been identified as chemoattractants for leukocytes.21 22 Migration to and infiltration into tissues by leukocytes as well as the subsequent activation of these cells are regulated by chemokines. IL-8 and MCP-1 are potent and selective chemoattractants for neutrophils and monocytes-macrophages, respectively. Increased local expression of IL-8 and MCP-1 has been detected in individuals with corneal inflammatory diseases.2 3 Inhibition of IL-8 or MCP-1 synthesis by corneal fibroblasts may thus reduce the extent of neutrophil or monocyte recruitment to the cornea as well as that of consequent corneal damage. Our results suggest that triptolide has therapeutic potential as an alternative to steroids for suppressing leukocyte infiltration into the cornea.
ICAM-1 is a cell surface glycoprotein of 76 to 114 kDa and a member of the immunoglobulin superfamily of proteins.23 It contributes to the local infiltration of leukocytes during immune responses by mediating the adhesion and activation of these cells through interaction with the ß2 integrin chain expressed on their surface.24 ICAM-1 is selectively expressed in the cornea in areas of inflammation.25 Furthermore, leukocyte infiltration into tissues is markedly reduced in ICAM-1-deficient mice compared with that in control animals.26 We have previously shown that exposure of corneal fibroblasts to TNF-
increases the adherence of neutrophils to these cells, indicating that ICAM-1 expressed by corneal fibroblasts in response to TNF-
is biologically active.14 Inhibition or modulation of the expression of ICAM-1 in corneal fibroblasts may thus provide a new therapeutic option in the treatment of corneal inflammatory diseases. Our data indicate that, although triptolide significantly inhibited the increase in the amount of ICAM-1 mRNA in human corneal fibroblasts induced by TNF-
, its effect on the expression of ICAM-1 on the cell surface was limited.
Triptolide and dexamethasone exert various effects on immune cells as well as on tissue-resident cells that participate in inflammatory responses. The similarity in the effects of these two compounds is dependent on cell type, however. Both dexamethasone and triptolide inhibit cytokine synthesis in monocytes,8 27 T cells,9 28 and macrophages,29 30 and induce apoptosis in T cells.31 32 Both agents inhibit phagocytosis by neutrophils,33 whereas dexamethasone also inhibits apoptosis in these cells.33 Triptolide inhibits IgG secretion from B cells,8 whereas dexamethasone has no such effect.34 We have shown that dexamethasone inhibits not only the synthesis but also the activation of matrix metalloproteinases in rabbit corneal fibroblasts,35 whereas triptolide inhibits only the synthesis of these enzymes.12 Steroids have been administered widely for their anti-inflammatory activity in human diseases, but they are not free of adverse effects. Such adverse reactions may be avoided if triptolide proves effective for the treatment of corneal inflammation. Triptolide has been shown to be effective in the treatment of several autoimmune diseases such as rheumatoid arthritis,7 lung fibrosis,36 and uveoretinitis37 in animal models. Furthermore, clinical studies of triptolide in patients with rheumatoid arthritis have shown that the drug is safe and clinically beneficial.38 39 Whether triptolide is a viable alternative to steroids for treatment of corneal inflammation and is devoid of adverse effects remain to be clarified.
The transcription factor NF-
B plays an important role in intracellular signaling induced by IL-1 or TNF-
and is therefore a potential target for new therapeutic approaches to inflammatory diseases. In the current study, triptolide inhibited the activation of NF-
B by IL-1ß in human corneal fibroblasts, suggesting that this effect of triptolide contributes to its inhibition of chemokine expression stimulated by proinflammatory cytokines. Triptolide has been shown to inhibit cytokine production in T cells9 and bronchial epithelial cells10 as well as to sensitize lung cancer cells to apoptosis40 by inhibition of NF-
B activity. The mechanism by which triptolide inhibits the activation of NF-
B remains to be determined.
AP-1 also contributes to IL-1 and TNF-
signaling pathways in many cell types. In the present study, however, the transactivation activity of AP-1 in corneal fibroblasts was not increased by IL-1ß. Although triptolide has been shown to inhibit AP-1 activity in articular chondrocytes41 and gastric cancer cells,42 it did not affect AP-1 activity in corneal fibroblasts.
We recently showed that neutrophils stimulate collagen degradation by corneal fibroblasts43 and that triptolide inhibits IL-1-induced collagen degradation by corneal fibroblasts.12 Interactions of inflammatory cells with resident corneal fibroblasts therefore very likely play an important role in corneal inflammation. The inhibition by triptolide of IL-8 and MCP-1 synthesis is not specific to corneal fibroblasts, given that this agent has been shown to exert a similar action in cultured bronchial epithelial cells.10 Nevertheless, our present results suggest that triptolide may be of therapeutic benefit in diseases characterized by corneal stromal inflammation.
| Footnotes |
|---|
Submitted for publication January 5, 2005; revised March 4, 2005; accepted March 9, 2005.
Disclosure: Y. Lu, None; K. Fukuda, None; Y. Nakamura (P); K. Kimura, None; N. Kumagai, None; T. Nishida (P)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Teruo Nishida, Department of Biomolecular Recognition and Ophthalmology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi 755-8505, Japan; tnishida{at}yamaguchi-u.ac.jp.
| References |
|---|
|
|
|---|
(CXCL-1), IL-8 (CXCL-8), and MCP-1 (CCL-2) in inflamed human corneas in vivo. Arch Ophthalmol. 2003;121:825831.
B transcriptional activation. J Biol Chem. 1999;274:1344313450.
and IL-4 on the expression of thymus- and activation-regulated chemokine in human corneal fibroblasts. Biochem Biophys Res Commun. 2000;279:15.[CrossRef][ISI][Medline][Order article via Infotrieve]
. Jpn J Ophthalmol. 2003;47:134141.[CrossRef][Medline][Order article via Infotrieve]
and IL-4 or IL-13. Invest Ophthalmol Vis Sci. 2000;41:14481453.
(TNF-
) in seasonal allergic conjunctivitis and vernal keratoconjunctivitis. Eur J Ophthalmol. 2003;13:606610.[ISI][Medline][Order article via Infotrieve]
production from monocytes: role of transcription factor NF-
B and implication for rheumatoid arthritis therapy. Eur J Pharmacol. 2004;501:199208.[CrossRef][ISI][Medline][Order article via Infotrieve]
B activation. Exp Mol Med. 2002;34:462468.[ISI][Medline][Order article via Infotrieve]
B activities. Mol Pharmacol. 2001;59:11961205.
B activation in gastric cancer cells. Oncogene. 2001;20:80098018.[CrossRef][ISI][Medline][Order article via Infotrieve]
This article has been cited by other articles:
![]() |
S. Nakao, Y. Hata, M. Miura, K. Noda, Y. N. Kimura, S. Kawahara, T. Kita, T. Hisatomi, T. Nakazawa, Y. Jin, et al. Dexamethasone Inhibits Interleukin-1{beta}-Induced Corneal Neovascularization: Role of Nuclear Factor-{kappa}B-Activated Stromal Cells in Inflammatory Angiogenesis Am. J. Pathol., September 1, 2007; 171(3): 1058 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Smith, D. Choi, T. J. Chipps, Y. Pan, D. O. Zamora, M. H. Davies, B. Babra, M. R. Powers, S. R. Planck, and J. T. Rosenbaum Unique Gene Expression Profiles of Donor-Matched Human Retinal and Choroidal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2676 - 2684. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lu, Y. Liu, K. Fukuda, Y. Nakamura, N. Kumagai, and T. Nishida Inhibition by triptolide of chemokine, proinflammatory cytokine, and adhesion molecule expression induced by lipopolysaccharide in corneal fibroblasts. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3796 - 3800. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |